BLA 020378 · Emd Serono
Gonal-F
Follitropin Alfa/Beta · Subcutaneous
OrphanLast checked: Nov 20, 2026Latest source record: Nov 21, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
Sep 29, 1997
Approved uses
2
Original approval plus efficacy supplements
Registered trials
62
13 Phase 3, 3 recruiting
FAERS reports
2,046
1,696 serious, 32 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 2, 2025.
GONAL-f is indicated for: GONAL-f is a gonadotropin indicated for: Women: Induction of ovulation and pregnancy in oligo-anovulatory infertile women for whom the cause of infertility is functional and not due to primary ovarian failure. ( 1.1 ) Development of multiple follicles in ovulatory infertile women as part of Assisted Reproductive Technology (ART) cycles. ( 1.2 ) Men: Induction of spermatogenesis in infertile men with primary and secondary hypogonadotropic hypogonadism for whom the cause of infertility is not due to primary testicular failure. ( 1.3 ) 1.1 Induction of ovulation and pregnancy in oligo-anovulatory infertile women for whom the cause of infertility is functional and not due to primary ovarian failure. 1.2 Development of multiple follicles in ovulatory infertile women as part of an assisted reproductive technology (ART) cycle. 1.3 Induction of spermatogenesis in infertile men with primary and secondary hypogonadotropic hypogonadism for whom the cause of infertility is not due to primary testicular failure.
Mechanism: GONAL-f stimulates ovarian follicular growth in women who do not have primary ovarian failure. In order to bring about final maturation of the follicle and ovulation in the absence of an endogenous LH surge, human chorionic gonadotropin (hCG) must be given, following the administration of GONAL-f, when monitoring of the patient indicates that sufficient follicular development is achieved. GONAL-f stimulates spermatogenesis in men with hypogonadotropic hypogonadism when administered with hCG.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 24, 2000 Supplement 6 · Efficacy LabelLetter
- Sep 29, 1997 Original approval · Type 3 - New Dosage Form
5 products under this application
- GONAL-F · FOLLITROPIN ALFA/BETA 150 IU/VIAL · INJECTABLE, SUBCUTANEOUS · Discontinued
- GONAL-F · FOLLITROPIN ALFA/BETA 450 IU/VIAL · INJECTABLE, SUBCUTANEOUS · Prescription
- GONAL-F · FOLLITROPIN ALFA/BETA 37.5 IU/VIAL · INJECTABLE, SUBCUTANEOUS · Discontinued
- GONAL-F · FOLLITROPIN ALFA/BETA 75 IU/VIAL · INJECTABLE, SUBCUTANEOUS · Discontinued
- GONAL-F · FOLLITROPIN ALFA/BETA 1,050 IU/VIAL · INJECTABLE, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Follitropin Alfa/Beta" as an intervention, any sponsor and status, largest first.
- A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00696800 · 1,509 participants · Start Jun 27, 2006 · Primary completion Nov 19, 2007
Drug: Corifollitropin alfa; RecFSH / Follitropin beta (Days 1 to 7) and 6 more · For: In Vitro Fertilization
- Efficacy and Safety Study of a Single Injection of SCH 900962 Versus Daily recFSH Injections in Women Undergoing Controlled Ovarian Stimulation (Study P06029)Pivotal-lookingCompleted
Organon and CoIndustry
NCT01144416 · 1,424 participants · Start Jun 2010 · Primary completion Jul 2011
Drug: SCH 900962 / Corifollitropin alfa / Org 36286; RecFSH / follitropin beta and 2 more · For: Infertility
Lund UniversityAcademic, hospital or other
NCT03737253 · 810 participants · Start Sep 2016 · Primary completion Dec 31, 2021
Drug: Follitropin alpha; Menotropin · For: Female Infertility
Sites: Poznan, Poland; Malmö, Sweden
- MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo TransferPivotal-lookingCompleted
Ferring PharmaceuticalsIndustry
NCT00884221 · 749 participants · Start Jul 2009 · Primary completion Jul 2010
Drug: Highly purified menotrophin; Recombinant FSH · For: Infertility
Sites: Anderlecht, Belgium; Brussels, Belgium; Edegem, Belgium · 25 sites in all
- Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist TreatmentPivotal-lookingRecruiting
Nanjing UniversityAcademic, hospital or other
NCT07128394 · 590 participants (planned) · Start Feb 1, 2024 · Primary completion Sep 30, 2026
Drug: Recombinant Luteinizing Hormone (rLH); Recombinant Follicle-Stimulating Hormone (rFSH) and 1 more · For: Infertility, Female; Luteinizing Hormone (LH)
Sites: Nanjing, China
- Effectiveness of Estradiol Valerate Pretreatment in Antagonist Protocol for Poor Ovarian Response PatientPivotal-lookingCompleted
Reproductive & Genetic Hospital of CITIC-XiangyaAcademic, hospital or other
NCT03300518 · 552 participants · Start Nov 15, 2017 · Primary completion Jun 18, 2021
Drug: Follitropin Beta;MSD; Ganirelix and 2 more · For: Infertility
Sites: Changsha, China
- Nordic Luveris StudyPivotal-lookingCompleted
Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
NCT00553293 · 526 participants · Start Aug 2003
Drug: recombinant luteinizing hormone (Luveris); recombinant follicle stimulating hormone (Gonal-f) · For: Infertility; In Vitro Fertilization
Sites: Copenhagen, Denmark
- Efficacy of Corifollitropin Alfa Versus Follitropin Beta in Aged IVF (In-vitro Fertilization) PatientsPivotal-lookingCompleted
Vietnam National UniversityAcademic, hospital or other
NCT02466204 · 400 participants · Start Jun 1, 2015 · Primary completion Aug 10, 2016
Drug: corifollitropin alfa; Follitropin Beta · For: Infertility
Sites: Ho Chi Minh City, Vietnam · 2 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- ovarian hyperstimulation syndrome696
- ascites223
- abdominal pain130
- abortion spontaneous123
- abdominal distension120
- nausea104
- dyspnoea100
- vomiting85
- inappropriate schedule of drug administration80
- drug ineffective78
- pleural effusion76
- off label use75
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 15 |
| 2005 | 21 |
| 2006 | 18 |
| 2007 | 45 |
| 2008 | 43 |
| 2009 | 44 |
| 2010 | 54 |
| 2011 | 65 |
| 2012 | 79 |
| 2013 | 109 |
| 2014 | 139 |
| 2015 | 114 |
| 2016 | 102 |
| 2017 | 174 |
| 2018 | 110 |
| 2019 | 165 |
| 2020 | 116 |
| 2021 | 45 |
| 2022 | 127 |
| 2023 | 143 |
| 2024 | 129 |
| 2025 | 100 |
| 2026 | 89 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment.
Marrs R, Meldrum D, Muasher S, et al. · Reprod Biomed Online 2004 · Clinical Trial, Comparative Study
- Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis.
Chua SJ, Mol BW, Longobardi S, et al. · Reprod Biol Endocrinol 2021 · Comparative Study, Meta-Analysis
- Recombinant human follicle-stimulating hormone injection versus Gonal-f® in controlled ovarian stimulation for assisted reproductive technology: A multicenter, randomized, assessor-blind, active-controlled phase III trial.
Bai H, Li J, Wang Y, et al. · Exp Cell Res 2026 · Randomized Controlled Trial, Multicenter Study
- Comparison of the efficacy and safety of a new recombinant human follicle-stimulating hormone (DA-3801) with follitropin-alpha (Gonal-F) in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology.
Moon SY, Choi YS, Ku SY, et al. · J Obstet Gynaecol Res 2007 · Clinical Trial, Phase III, Comparative Study
- The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review.
Velthuis E, Hubbard J, Longobardi S, et al. · Adv Ther 2020 · Research Support, Non-U.S. Gov't, Systematic Review
- Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study.
Olivennes F, Howles CM, Borini A, et al. · Reprod Biomed Online 2009 · Clinical Trial, Phase III, Clinical Trial, Phase IV
Sponsor: Emd Serono
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.